





## Notes

1 Atorvastatin 80 mg and rosuvastatin 40mg give approximately equivalent lowering of LDL-C and should be prescribed generically.

In some cases, it is suitable to start at lower doses (e.g., elderly, lower body weight, renal impairment, previous statin side effects, patient preference, drug interactions).

If no contra-indications always consider dose titration to maximum and/or maximum tolerated dosage (in line with manufacturers guidance). <u>Atorvastatin</u> / <u>Rosuvastatin</u>.

2 PCSK9 inhibitors (alirocumab and evolocumab)

According to NICE TA 293 (alirocumab) and TA294 (evolocumab):

<u>High risk</u> of cardiovascular disease is defined as a history of any of the following: acute coronary syndrome (such as myocardial infarction or unstable angina requiring hospitalisation), coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke, peripheral arterial disease.

<u>Very high risk</u> of cardiovascular disease is defined as recurrent cardiovascular events or cardiovascular events in more than one vascular bed (that is, poly-vascular disease).

- 3 <u>Inclisiran</u> is recommended (in line with NICE TA 733) only if there is a history of any of the following cardiovascular events: acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation), coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke or peripheral arterial disease, and low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy and that the company provides inclisiran according to the commercial arrangement
- 4 <u>Bempedoic acid</u> is NICE approved (TA694) in combination with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

Bempedoic may increase uric acid levels which may increase the risk of gout.

## **Further information**

Full prescribing details for individual medicines may be found in the Summary of Product Characteristics

The updated NICE endorsed lipid lowering pathway (December 2021) - which includes secondary prevention

NICE endorsed guidelines for the management of statin intolerance (August 2021)

## Lead Authors:

Dr Kate Shipman, Consultant Chemical Pathologist UHS (West)

Alison Warren, Consultant Pharmacist Cardiology, UHS and Sussex CCGs

Version 1	March 2022	Approved Sussex ICS APC MARCH 2022
Review date	March 2024	